One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.08.008
Volume 84, Issue 4, October 2023, Pages e81-e91
The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health
Alexander P. Cole a,*, Natasha Gupta b , Stacy Loeb
doi : 10.1016/j.eururo.2023.06.020
Volume 84, Issue 4, October 2023, Pages 357-358
Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach
Eveline A.M. Heijnsdijk *, Harry J. de Koning
doi : 10.1016/j.eururo.2023.05.022
Volume 84, Issue 4, October 2023, Pages 359-360
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
Devaki Shilpa Surasi a,*, Matthias Eiber b , Tobias Maurer c,d , Mark A. Preston e , Brian T. Helfand f , David Josephson g,h , Ashutosh K. Tewari i , Diederik M. Somford j,k , Soroush Rais-Bahrami l , Bridget F. Koontz m,y, Peter J. Bostrom n,o , Albert Chau p , Phillip Davis q , David M. Schuster r , Brian F. Chapin s , on behalf of the LIGHTHOUSE Study Group
doi : 10.1016/j.eururo.2023.06.018
Volume 84, Issue 4, October 2023, Pages 361-370
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now
´de´ric Pouliot a,b,*, Louise Emmett
doi : 10.1016/j.eururo.2023.07.007
Volume 84, Issue 4, October 2023, Pages 371-372
A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee y,*, Haley Gittleman y, Chana Weinstock, Daniel Suzman, Erik Bloomquist, Sundeep Agrawal, Michael Brave, Jamie Brewer, Jaleh Fallah, Harpreet Singh, Shenghui Tang, Amna Ibrahim, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
doi : 10.1016/j.eururo.2023.05.030
Volume 84, Issue 4, October 2023, Pages 373-378
Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification
Amanda E. Hird a , Julia´n Chavarriaga a , Aly-Khan A. Lalani b , Christopher J.D. Wallis a
doi : 10.1016/j.eururo.2023.06.025
Volume 84, Issue 4, October 2023, Pages 379-380
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
Aristotelis Bamias a,y,*, Arnulf Stenzl b,y, Stephanie L. Brown c , Laurence Albiges d , Marko Babjuk e , Alison Birtle f , Alberto Briganti g , Maximilian Burger h , Ananya Choudhury i , Maurizio Colecchia j , Maria De Santis k , Stefano Fanti l , Vale´rie Fonteyne m , Michele Gallucci n , Juan Go´mez Rivas o , Robert Huddart p , Kerstin Junker q , Stephanie Kroeze r , Yohann Loriot d , Axel Merseburger s , Rodolfo Montironi t , Andrea Necchi j , Christoph Oing u , Jan Oldenburg v , Piet Ost w,x , Michael Pinkawa y , Maria J. Ribal z , Morgan Roupreˆt aa , Harriet Thoeny bb , Thomas Zilli cc , Peter Hoskin
doi : 10.1016/j.eururo.2023.05.005
Volume 84, Issue 4, October 2023, Pages 381-389
Oligometastatic Bladder Cancer: Defining a Novel Entity
Chris Labaki, Eddy Saad, Toni K. Choueiri y, Joaquim Bellmunt
doi : 10.1016/j.eururo.2023.06.003
Volume 84, Issue 4, October 2023, Pages 390-392
Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials
Pramit Khetrapal a,b,c,y,*, Joanna Kae Ling Wong d,e,y, Wei Phin Tan f , Thiara Rupasinghe a , Wei Shen Tan a,g , Stephen B. Williams h , Stephen A. Boorjian i , Carl Wijburg j , Dipen J. Parekh k , Peter Wiklund l , Nikhil Vasdev m,n , Muhammad Shamim Khan o , Khurshid A. Guru p , James W.F. Catto q,r,Ã , John D. Kelly
doi : 10.1016/j.eururo.2023.04.004
Volume 84, Issue 4, October 2023, Pages 393-405
Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review
Robert J. Motzer a,*, Pratik P. Rane b , Todd L. Saretsky b , Deepshikha Pawar c , Allison Martin Nguyen b , Murali Sundaram b , Joseph Burgents b , Rishabh Pandey d , Katja Rudell
doi : 10.1016/j.eururo.2023.07.006
Volume 84, Issue 4, October 2023, Pages 406-417
Three-dimensional Virtual Models of the Kidney with Colored Perfusion Regions: A New Algorithm-based Tool for Optimizing the Clamping Strategy During Robot-assisted Partial Nephrectomy
Daniele Amparore a,* ,y, Federico Piramide a,y, Enrico Checcucci b , Paolo Verri a , Sabrina De Cillis a , Alberto Piana a , Gabriele Volpi a , Giovanni Busacca a , Marco Colombo a , Cristian Fiori a,Ã , Francesco Porpiglia
doi : 10.1016/j.eururo.2023.04.005
Volume 84, Issue 4, October 2023, Pages 418-425
A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer
Ivo I. de Vos y,*, Annick Meertens y, Rene´e Hogenhout, Sebastiaan Remmers, Monique J. Roobol, on behalf of the ERSPC Rotterdam Study Group
doi : 10.1016/j.eururo.2023.03.016
Volume 84, Issue 4, October 2023, Pages 426-434
Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Matthew R. Cooperberg
doi : 10.1016/j.eururo.2023.05.002
Volume 84, Issue 4, October 2023, Pages 435-436
Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer
David Chang a,b Sree Appu c Shankar Siva
doi : 10.1016/j.eururo.2023.05.024
Volume 84, Issue 4, October 2023, Pages 436-437
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
Martin Sj?str?m a Anders Bjartell
doi : 10.1016/j.eururo.2023.04.029
Volume 84, Issue 4, October 2023, Pages 437-438
Re: Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma with Limited Retroperitoneal Lymphadenopathy
Jianliang Liu a,b Benjamin Thomas b Nathan Lawrentschuk
doi : 10.1016/j.eururo.2023.05.025
Volume 84, Issue 4, October 2023, Pages 438-439
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study
Marco Moschini * Andrea Salonia Alberto Briganti Francesco Montorsi
doi : 10.1016/j.eururo.2023.03.010
Volume 84, Issue 4, October 2023, Pages 439-440
Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial
Michael O’Callaghan a,*, Adelaide Bladder Cancer Research Group
doi : 10.1016/j.eururo.2023.05.026
Volume 84, Issue 4, October 2023, Pages 440-441
Industry Payments to American Editorial Board Members of Major Urology Journals
David-Dan Nguyen a,y, Liam Murad b,y, Anne Xuan-Lan Nguyen b , Anudari Zorigtbaatar c , David Bouhadana b , Claudia Deyirmendjian d , Kevin C. Zorn e , Dean Elterman a , Bilal Chughtai f , Rashid K. Sayyid a , Muhieddine Labban g , Quoc-Dien Trinh g , Christopher J.D. Wallis h , Naeem Bhojani
doi : 10.1016/j.eururo.2023.04.017
Volume 84, Issue 4, October 2023, Pages 442-443
Re: Elizabeth J. Schafer, Ahmedin Jemal, Daniel Wiese, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023;84:117–26
Po-Ren Hsiao a,b Wen-Wei Sung
doi : 10.1016/j.eururo.2023.06.033
Volume 84, Issue 4, October 2023, Page e92
Re: Toni K. Choueiri, Thomas Powles, Laurence Albiges, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767–78
Clara Cerrato a Benjamin Pradere b Maria Carmen Mir
doi : 10.1016/j.eururo.2023.06.027
Volume 84, Issue 4, October 2023, Page e93
Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6
Luke C. Ardolino a,b,c Rachel Dear a,b,c Andrew J. Armstrong d Silke Gillessen e,f,g Anthony M. Joshua
doi : 10.1016/j.eururo.2023.04.043
Volume 84, Issue 4, October 2023, Pages e94-e95
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116
Meredith M. Regan a,* Michael B. Atkins b David F. McDermott
doi : 10.1016/j.eururo.2023.05.041
Volume 84, Issue 4, October 2023, Pages e96-e97
Corrigendum to “Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials� [Eur Urol. 2023;84:393–405]
Pramit Khetrapal a,b,c,y,*, Joanna Kae Ling Wong d,e,y, Wei Phin Tan f , Thiara Rupasinghe a , Wei Shen Tan a,g , Stephen B. Williams h , Stephen A. Boorjian i , Carl Wijburg j , Dipen J. Parekh k , Peter Wiklund l , Nikhil Vasdev m,n , Muhammad Shamim Khan o , Khurshid A. Guru p , James W.F. Catto q,r,Ã , John D. Kelly
doi : 10.1016/j.eururo.2023.06.023
Volume 84, Issue 4, October 2023, Pages e98-e99
Congress Calendar
doi : 10.1016/j.eururo.2023.08.009
Volume 84, Issue 4, October 2023, Pages e100-e102
